Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis

Abstract

In patients with aggressive non-Hodgkin lymphomas (NHLs), T-cell lymphoma (TCL) confers a poor prognosis. Since rituximab has increased survival for patients with diffuse large B-cell lymphoma (DLBCL), we hypothesized that the difference in outcome by phenotype became more pronounced recently and evaluated these changes using the Surveillance, Epidemiology, and End Results (SEER) Program. Cases diagnosed in 1992–1997 (era 1) and 1998–2003 (era 2) were evaluated for outcomes according to immunophenotype and era. A total of 22 252 patients with DLBCL and 2222 with TCL were included. In both eras, patients with TCL were more likely to die from their disease than those with DLBCL. Death from NHL decreased significantly from era 1 to era 2 for all DLBCL patients grouped by age and stage but in none of the TCL groups. Improved outcomes for DLBCL after the introduction of rituximab-based therapies in 1997 have no counterpart in patients with TCL, pointing to the need for new therapies to treat TCL.

Keywords:

• T-cell lymphoma
• Diffuse large B-cell lymphoma
• SEER

Declaration of interest: I.S.L is supported by the National Institutes of Health (NIH) grants NIH CA 109335 and NIH CA 122105, and the Dwoskin Family and Fidelity Foundations.